Rain Therapeutics Announces an Oral Presentation at the Connective Tissue Oncology Society Annual Meeting

Rhea-AI Summary

Rain Therapeutics Inc. (NASDAQ: RAIN) announced an oral presentation on its lead product candidate, milademetan, at the Connective Tissue Oncology Society Annual Meeting in Vancouver, Canada, from November 16-19, 2022. The presentation, titled Sustained disease control with MDM2 inhibitor milademetan in patients with advanced dedifferentiated liposarcoma, will be given by Dr. Mrinal M. Gounder on November 17, 2022. Rain Therapeutics focuses on precision oncology, developing therapies targeting oncogenic drivers, alongside a preclinical program inhibiting RAD52.

Positive

• Presentation of milademetan could increase visibility and interest in Rain's lead product.
• Focus on precision oncology aligns with current market trends toward targeted therapies.

Negative

• None.

NEWARK, Calif., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (Rain), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced an oral presentation at the Connective Tissue Oncology Society (CTOS) Annual Meeting taking place on November 16-19, 2022 in Vancouver, BC, Canada.

Presentation Title:	Sustained disease control with MDM2 inhibitor milademetan in patients with advanced dedifferentiated liposarcoma
Session:	Session 3: Medical & Pediatric Oncology and Clinical Trials
Presenter:	Mrinal M. Gounder, M.D., Associate Attending Physician Memorial Sloan Kettering Cancer Center and Weill Cornall Medical Center, New York, NY, USA
Session Date and Time:	Thursday, November 17, 2022; 1:00-2:30 pm Pacific Time
Location:	VCC: East Exhibition Hall B

A copy of the presentation materials can be accessed by visiting the "Resources” section of the Rain website after the conclusion of the presentation and will be archived on the Rain website.

About Rain Therapeutics Inc.
Rain Therapeutics Inc. is a late-stage precision oncology company developing therapies that target oncogenic drivers to genetically select patients it believes will most likely benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors’ underlying genetics rather than histology. Rain’s lead product candidate, milademetan, is a small molecule, oral inhibitor of MDM2-p53 complex that reactivates p53. In addition to milademetan, Rain is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.

Investor Contact
Dan Ferry
LifeSci Advisors
+1.617.430.7576
daniel@lifesciadvisors.com

Media Contact
Jordyn Temperato
LifeSci Communications
jtemperato@lifescicomms.com

FAQ

What is Rain Therapeutics Inc. known for?

Rain Therapeutics is focused on developing precision oncology therapies, particularly targeting the MDM2-p53 complex with its lead product milademetan.

When and where is Rain Therapeutics presenting milademetan?

Rain is presenting milademetan on November 17, 2022, at the Connective Tissue Oncology Society Annual Meeting in Vancouver, Canada.

Who will present the milademetan findings at the CTOS Annual Meeting?

Dr. Mrinal M. Gounder will present the findings on milademetan at the CTOS Annual Meeting.

What is the significance of milademetan in cancer treatment?

Milademetan is an oral small molecule inhibitor of the MDM2-p53 complex, which reactivates p53, a crucial tumor suppressor protein, making it significant for treating certain cancers.

How can I access the presentation materials for milademetan?

The presentation materials will be available in the Resources section of the Rain Therapeutics website after the conclusion of the presentation.